Israel-based Teva Pharmaceutical Industries Ltd has revealed in its most recent filing with the Securities and Exchange Commission that it has identified compliance issues at some of its affiliates across several countries, the FCPA blog reports.
The SEC subpoenaed Teva back in July 2012, the Wall Street Journal reported at the time, as part of an investigation into possible violations of the Foreign Corrupt Practices Act, a U.S. anti-bribery law. The agency was seeking documents connected to Teva’s affiliates in Latin America.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
